MAPT and Alzheimer disease: Assay conditions used here also likely do not fully replicate the structures of AD tau filaments as we know them to occur in brain [35], limiting their utility in addressing the complexities of how different protein seeds could impact formation and/or propagation of heterologous misfolded proteins and their structures that occur in vivo.